Gazyva

In next-gen BTK battle, AbbVie and J&J tout pivotal data backing Imbruvica as a combo treatment
In next-gen BTK battle, AbbVie and J&J tout pivotal data backing Imbruvica as a combo treatment
Endpoints
AstraZeneca
JNJ
AbbVie
clinical trials
CLL
Gazyva
Imbruvica
Venclexta
Flag link:
Roche steers Gazyva into a new PhIII program after combo shows promise in lupus nephritis study
Roche steers Gazyva into a new PhIII program after combo shows promise in lupus nephritis study
Endpoints
Roche
monoclonal antibodies
Gazyva
lupus
kidney disease
clinical trials
Flag link:
After touting Gazyva's potential in lupus, Roche nabs 'breakthrough' ahead of PhIII
After touting Gazyva's potential in lupus, Roche nabs 'breakthrough' ahead of PhIII
Endpoints
Roche
Gazyva
lupus nephritis
Flag link:
Roche touts phase 2 Gazyva data in lupus patients with a potentially fatal kidney complication
Roche touts phase 2 Gazyva data in lupus patients with a potentially fatal kidney complication
Fierce Pharma
Roche
FDA
lupus nephritis
Gazyva
Flag link:
ASCO Soundbites, vol. 3: Real-time approvals, Pfizer's second rodeo and 'the busiest ASCO ever'
ASCO Soundbites, vol. 3: Real-time approvals, Pfizer's second rodeo and 'the busiest ASCO ever'
Fierce Pharma
ASCO 2019
Merck
Keytruda
FDA
Pfizer
AstraZeneca
Regeneron
Libtayo
Venclexta
Gazyva
Flag link:
Genentech Submits sNDA For Venclexta and Gazyva Combo for Chronic Lymphocytic Leukemia
Genentech Submits sNDA For Venclexta and Gazyva Combo for Chronic Lymphocytic Leukemia
CP Wire
Genentech
Roche
AbbVie
chronic lymphocytic leukemia
Gazyva
Venclexta
Flag link:
Genentech Submits sNDA For Venclexta and Gazyva Combo for Chronic Lymphocytic Leukemia
Genentech
Roche
AbbVie
chronic lymphocytic leukemia
Gazyva
Venclexta
Flag link:
FDA Gives Greenlight to Janssen and AbbVie's Imbruvica for the 10th Time
FDA Gives Greenlight to Janssen and AbbVie's Imbruvica for the 10th Time
BioSpace
Imbruvica
Janssen
AbbVie
Roche
Gazyva
chronic lymphocytic leukemia
small lymphocytic lymphoma
FDA
Flag link:
Roche and AbbVie Push Towards First-Line CLL Treatment
Roche and AbbVie Push Towards First-Line CLL Treatment
BioSpace
Roche
Genentech
AbbVie
clinical trials
Venclexta
Gazyva
CLL
chronic lymphocytic leukemia
Flag link:
Priority Review for Imbruvica-Gazyva combo to treat CLL, SLL
Priority Review for Imbruvica-Gazyva combo to treat CLL, SLL
BioCentury
AbbVie
FDA
priority review
Imbruvica
Gazyva
CLL
SLL
Flag link:
AbbVie eyes Imbruvica expansion in CLL as Gazyva pairing hits its marks
AbbVie eyes Imbruvica expansion in CLL as Gazyva pairing hits its marks
Fierce Pharma
AbbVie
Imbruvica
CLL
Gazyva
Flag link:
Cancer Space Update: Label Expansion for Three Major Drugs
Cancer Space Update: Label Expansion for Three Major Drugs
Yahoo/Zacks.com
cancer
labeling
AstraZeneca
Faslodex
Pfizer
Sutent
kidney cancer
Roche
Gazyva
follicular lymphoma
Flag link:
Late-stage study of Roche's Gazyva in large B-cell lymphoma fails to hit main goal
Late-stage study of Roche's Gazyva in large B-cell lymphoma fails to hit main goal
First Word Pharma
Roche
Gazyva
large B-cell lymphoma
clinical trials
Flag link:
Roche's Hematology Franchise Almost 100% Protected From Biosimilars
Roche's Hematology Franchise Almost 100% Protected From Biosimilars
Seeking Alpha
Roche
hematology
biosimilars
Gazyva
Rituxan
Flag link:
Roche's Gazyva notches early trial success
Roche's Gazyva notches early trial success
BioPharma Dive
Roche
Gazyva
clinical trials
rituximab
follicular lymphoma
Flag link:
Roche Holding Moves Ahead in Cancer Drugs Race; Wins Expanded FDA Approval for Gazyva
Roche Holding Moves Ahead in Cancer Drugs Race; Wins Expanded FDA Approval for Gazyva
Bidness, ETC
Roche
FDA
Gazyva
follicular lymphoma
Flag link:
Biosimilars will cut top 10 vulnerable biologics almost in half by 2020: Morningstar
Biosimilars will cut top 10 vulnerable biologics almost in half by 2020: Morningstar
Fierce Pharma Marketing
biosimilars
AbbVie
Roche
Amgen
Rituxan
Herceptin
Avastin
Neupogen
Neulasta
Epogen
Humira
Perjeta
Gazyva
Flag link:
Roche's Gazyva doubles remission time for non-Hodgkin lymphoma patients
Roche's Gazyva doubles remission time for non-Hodgkin lymphoma patients
Fierce Pharma
Roche
Gazyva
non-Hodgkin's lymphoma
ASCO
Flag link:
3 Breakthrough Drugs Yield 1 Instant Blockbuster
3 Breakthrough Drugs Yield 1 Instant Blockbuster
Motley Fool
Roche
Gazyva
Imbruvica
JNJ
Gilead Sciences
Sovaldi
mantle cell lymphoma
chronic lymphocytic leukemia
leukemia
Biogen
hepatitis
hepatitus C
Flag link:
Here's Why Biogen Could Be in Store for a Big 2014
Here's Why Biogen Could Be in Store for a Big 2014
Motley Fool
Biogen Idec
Tecfidera
Eloctate
Alprolix
daclizumab
Gazyva
Flag link:

Pages